Best Stock Investments this April 2026

Devon Energy (DVN) stands out as a top-rated oil and gas producer, presenting significant upside potential before April 2026 amidst current market turbulence. With a robust 1-year return of 39.24% and a five-year return of 135.01%, investors can expect reliable income from its 2.08% dividend yield. Analysts are optimistic, with a median 12-month price target of $50.00, suggesting strong growth prospects.

Analysts project an average price target of $51.88 for Devon Energy, with estimates ranging from $41.00 to $67.00, indicating a potential increase of 6.33% from its last closing price of $48.79.

Marathon Petroleum (MPC), the largest oil refiner in the U.S., is positioned for strong returns, currently trading at about $234. With a solid 1.91% dividend yield and impressive 1-year and 5-year returns of 68.52% and 363.87%, respectively, it's attracting attention from analysts, who generally rate it as a Buy. The consensus suggests that MPC may be undervalued by 61.5%, making it an attractive option for investors looking for growth and reliable income.

Marathon Petroleum (MPC) has a consensus rating of 'Buy' from 13 analysts, with 15% recommending a 'Strong Buy' and 46% a 'Buy'.

Two analysts have raised their earnings estimates for fiscal 2026, increasing the Zacks Consensus Estimate to $14.45 per share, with an average earnings surprise of +32.7%.

Our Discounted Cash Flow analysis indicates that Marathon Petroleum is undervalued by 61.5%.

Moderna Inc. (MRNA) has demonstrated a robust performance with a 66.78% return over the past year, highlighting its potential for future growth in the biotech sector. Analysts have a consensus rating of Hold, with a median 12-month price target of $35.00, indicating a cautious outlook among experts, as only 8% recommend buying the stock. While the company has faced significant challenges with a 5-year return of -56.60%, its strong year-to-date performance positions it as a noteworthy consideration for investors seeking opportunities in biotech.

Moderna (MRNA) has a consensus rating of Hold from 12 analysts, with 0% recommending Strong Buy, 8% Buy, 67% Hold, 25% Sell, and 0% Strong Sell.

The average 12-month price target for MRNA, based on 18 analysts, is $36.13, with a high of $69.00 and a low of $12.00, indicating a potential decline of 29.68% from its last price of $51.38.

Texas Pacific Land Corp. (TPL) stands out as a top performer in the S&P 500, boasting a remarkable 75.8% gain year-to-date, largely driven by the strength of the resource sector. With a solid dividend yield of 0.41% and impressive long-term returns—218.39% over five years—TPL is positioned as an attractive option for investors looking for growth and stability.

TPL's stock has risen about 30.76% since coverage began, and its perpetual royalty model and high capital efficiency suggest strong long-term wealth compounding potential.

As of March 23, 2026, TPL shows a bullish trend with no negative signals and four positive signals, indicating strong mid-term potential despite resistance levels at $547.60 and $560.83.

The all-time high closing price for TPL stock was $571.92 on November 22, 2024.

TPL has a consensus analyst rating of 'Buy' from one analyst, with 100% recommending Buy and none suggesting Hold or Sell.